Management of acute metabolic decompensation in maple syrup urine disease: a multi-center study
- PMID: 10221014
- DOI: 10.1046/j.1442-200x.1999.4121044.x
Management of acute metabolic decompensation in maple syrup urine disease: a multi-center study
Abstract
Background: Therapeutic modalities in acute metabolic decompensation in maple syrup urine disease (MSUD) are variable, and outcomes of each therapeutic measure have been known only individually. Factors that affect neurological outcome are not clear.
Methods: A questionnaire was sent throughout Japan to each pediatrician treating any of the 42 MSUD patients.
Results: Necessary information was available for 13 patients through the questionnaire, and through a publication for one patient. In nine of the 14 patients episodes of metabolic decompensation developed in the neonatal period. In the other five, the onset of disease was delayed until infancy or later. In the nine patients with neonatal onset, a pretreatment level of plasma leucine greater than 40 mg/100 mL or a duration of altered level of alertness longer than 10 days was associated with a poor neurological outcome. The therapeutic measures employed included intravenous infusion of glucose and electrolyte solution or hypertonic glucose and electrolyte solution, exchange transfusion, peritoneal dialysis, a large dose of thiamine and intravenous hyperalimentation. All patients had survived the episodes and were alive at the time of the survey. Five of the nine patients with neonatal onset have developed neurological sequelae to varying degrees. Episodes of metabolic decompensation in infancy or thereafter did not affect, or only minimally affected, the neurological outcome.
Conclusion: Therapeutic goals to improve neurological outcome are to shorten the duration of the altered level of consciousness, and to minimize the peak plasma leucine level as much as possible.
Similar articles
-
Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease.Intensive Care Med. 2001 Nov;27(11):1798-806. doi: 10.1007/s00134-001-1124-2. Epub 2001 Oct 25. Intensive Care Med. 2001. PMID: 11810125
-
Predictors of acute metabolic decompensation in children with maple syrup urine disease at the emergency department.Eur J Pediatr. 2020 Jul;179(7):1107-1114. doi: 10.1007/s00431-020-03602-x. Epub 2020 Feb 11. Eur J Pediatr. 2020. PMID: 32048023
-
Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease.J Inherit Metab Dis. 2017 Nov;40(6):783-792. doi: 10.1007/s10545-017-0083-x. Epub 2017 Sep 13. J Inherit Metab Dis. 2017. PMID: 28905140
-
Successful pregnancy in maple syrup urine disease: a case report and review of the literature.Nutr J. 2018 May 12;17(1):51. doi: 10.1186/s12937-018-0357-7. Nutr J. 2018. PMID: 29753318 Free PMC article. Review.
-
[Anaesthesia in patients with maple syrup urine disease. Case report and perioperative anaesthetic management].Anaesthesist. 2010 Oct;59(10):914-7. doi: 10.1007/s00101-010-1762-2. Epub 2010 Sep 9. Anaesthesist. 2010. PMID: 20827453 Review. German.
Cited by
-
Animal models of maple syrup urine disease.J Inherit Metab Dis. 2009 Apr;32(2):229-46. doi: 10.1007/s10545-009-1086-z. Epub 2009 Mar 9. J Inherit Metab Dis. 2009. PMID: 19263237 Review.
-
Haemodialysis is an effective treatment in acute metabolic decompensation of maple syrup urine disease.Mol Genet Metab Rep. 2015 Jul 10;4:46-8. doi: 10.1016/j.ymgmr.2015.07.001. eCollection 2015 Sep. Mol Genet Metab Rep. 2015. PMID: 26937409 Free PMC article.
-
Molecular basis of various forms of maple syrup urine disease in Chilean patients.Mol Genet Genomic Med. 2021 May;9(5):e1616. doi: 10.1002/mgg3.1616. Epub 2021 May 6. Mol Genet Genomic Med. 2021. PMID: 33955723 Free PMC article.
-
Maple syrup urine disease mutation spectrum in a cohort of 40 consanguineous patients and insilico analysis of novel mutations.Metab Brain Dis. 2019 Aug;34(4):1145-1156. doi: 10.1007/s11011-019-00435-y. Epub 2019 May 22. Metab Brain Dis. 2019. PMID: 31119508
-
In silico analysis of novel mutations in maple syrup urine disease patients from Iran.Metab Brain Dis. 2017 Feb;32(1):105-113. doi: 10.1007/s11011-016-9867-1. Epub 2016 Aug 10. Metab Brain Dis. 2017. PMID: 27507644
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical